Cargando…
Lapatinib-induced inhibition of ovarian function is counteracted by the STAT3 pathway both in vivo and in vitro
Autores principales: | Liao, Qiuyue, Feng, Xue, Li, Xi, Chen, Ge, Chen, Jing, Yang, Bin, Li, Kezhen, Ai, Jihui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129968/ https://www.ncbi.nlm.nih.gov/pubmed/33982768 http://dx.doi.org/10.3892/or.2021.8074 |
Ejemplares similares
-
Lapatinib-induced inhibition of ovarian function is counteracted by the STAT3 pathway both in vivo and in vitro
por: Liao, Qiuyue, et al.
Publicado: (2020) -
Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models
por: Lubet, Ronald A., et al.
Publicado: (2019) -
The effect of NFATc1 on vascular generation and the possible underlying mechanism in epithelial ovarian carcinoma
por: Li, Long, et al.
Publicado: (2022) -
Clinical characteristics, pregnancy outcomes and ovarian function of pregnancy-associated breast cancer patients: a retrospective age-matched study
por: Liao, Qiuyue, et al.
Publicado: (2022) -
Minicircle DNA-Mediated CAR T Cells Targeting CD44 Suppressed Hepatocellular Carcinoma Both in vitro and in vivo [Corrigendum]
Publicado: (2020)